Ilypsa
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ilypsa
USP And Dexcel Pick Up Teva OTC Brands
Teva has struck a deal with USP in Poland that will see the Israeli company divest multiple consumer health brands. Meanwhile, Dexcel Pharma has acquired eight OTC brands from Teva in the UK.
UK’s Dexcel Pharma Snaps Up Eight OTC Brands From Teva
Dexcel Pharma has acquired eight OTC brands from Teva, including Bisodol Indigestion Relief Tablets, erectile dysfunction treatment Liberize and Yeast Vite supplements. Teva told HBW Insight it remains committed to the consumer health market despite a number of recent brand divestments.
Finance Watch: $2.2bn In New Funding Sources In February, So Far
Private Company Edition: New capital for health care and life science innovations include a fund for royalty deals, additional anti-infective funding, early-stage money and public health-focused cash. Also, Day One reveals a $130m series B venture round and Notch closes an $85m series A round.
Eisai Exits Dermatology Through Roivant Deal
Eisai has followed in the footsteps of Japanese peer Astellas by divesting assets in the dermatology area, this time through a deal with Roivant for a clinical stage atopic dermatitis therapy that it sees as no longer fitting into its strategic priorities.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice